Identification and Management of Cardiometabolic Risk in Canada: A Position Paper by the Cardiometabolic Risk Working Group (Executive Summary)

详细信息    查看全文

• 作者：Cardiometabolic Risk Working Group ; Executive Committee ; Lawrence A. Leiter ; MD ; FRCPC ; FACP^a ; ^b ; ^{LeiterL@smh.ca} (Chair) ; David H. Fitchett ; MD ; FRCPC^a ; ^b ; Richard E. Gilbert ; MD ; PhD ; FRCPC ; FRACP^a ; ^b ; Milan Gupta ; MD ; FRCPC^a ; ^b ; ^c ; ^d ; G.B. John Mancini ; MD ; FRCPC ; FACC^e ; Philip A. McFarlane ; MD ; PhD ; FRCPC^a ; ^b ; Robert Ross ; PhD^f ; Hwee Teoh ; PhD^a ; Subodh Verma ; MD ; PhD ; FRCSC ; FAHA^a ; ^b ; Working Group ; Sonia Anand ; MD ; PhD ; FRCPC^d ; Kathryn Camelon ; RD ; CDE^g ; Chi-Ming Chow ; MDCM ; MSc ; FRCPC ; FACC^a ; ^b ; Jafna L. Cox ; BA ; MD ; FRCPC ; FACC^h ; Jean-Pierre Despré ; s ; PhD ; FAHAⁱ ; Jacques Genest ; MD ; FRCPC^j ; Stewart B. Harris ; MD ; MPH ; FCFP ; FACPM^k ; David C.W. Lau ; MD ; PhD ; FRCPC^l ; Richard Lewanczuk ; MD ; PhD^m ; Peter P. Liu ; MD ; MSc ; FRCPC^b ; ^e ; Eva M. Lonn ; MD ; MSc ; FRCPC ; FACC^e ; Ruth McPherson ; MD ; PhD ; FRCPCⁿ ; Paul Poirier ; MD ; PhD ; FRCPC ; FACC ; FAHA^h ; Shafiq Qaadri ; MD ; MPP^o ; Ré ; mi Rabasa-Lhoret ; MD ; PhD^p ; Simon W. Rabkin ; MD ; FRCPC ; FACC^e ; Arya M. Sharma ; MD ; PhD ; FRCPC^m ; Andrew W. Steele ; MD ; FRCPC^q ; James A. Stone ; MD ; PhD ; FRCPC ; FAACVPR ; FACC^l ; Jean-Claude Tardif ; MD ; FRCPC ; FACC^r ; Sheldon Tobe ; MD ; FRCPC^b ; ^s ; Ehud Ur ; MB ; FRCP^e
• 刊名：Canadian Journal of Cardiology
• 出版年：2011
• 出版时间：March-April 2011
• 年：2011
• 卷：27
• 期：2
• 页码：124-131
• 全文大小：781 K

文摘

With the objectives of clarifying the concepts related to ¡°cardiometabolic risk,?¡°metabolic syndrome?and ¡°risk stratification?and presenting practical strategies to identify and reduce cardiovascular risk in multiethnic patient populations, the Cardiometabolic Working Group presents an executive summary of a detailed analysis and position paper that offers a comprehensive and consolidated approach to the identification and management of cardiometabolic risk. The above concepts overlap and relate to the atherogenic process and development of type 2 diabetes. However, there is confusion about what these terms mean and how they can best be used to improve our understanding of cardiovascular disease treatment and prevention. The concepts related to cardiometabolic risk, pathophysiology, and strategies for identification and management (including health behaviours, pharmacotherapy, and surgery) in the multiethnic Canadian population are presented. ¡°Global cardiometabolic risk?is proposed as an umbrella term for a comprehensive list of existing and emerging factors that predict cardiovascular disease and/or type 2 diabetes. Health behaviour interventions (weight loss, physical activity, diet, smoking cessation) in people identified at high cardiometabolic risk are of critical importance given the emerging crisis of obesity and the consequent epidemic of type 2 diabetes. Vascular protective measures (health behaviours for all patients and pharmacotherapy in appropriate patients) are essential to reduce cardiometabolic risk, and there is growing consensus that a multidisciplinary approach is needed to adequately address cardiometabolic risk factors. Health care professionals must also consider ethnicity-related risk factors in order to appropriately evaluate all individuals in their diverse patient populations.